Roshdy, W. H., M. F. Abdelhameed, H. A. Rashed, M. S. Abdellateif, A. Salamony, S. A. S. El-Rahman, and S. A. B. R. Y. SHAARAWY, "ASSESSMENT OF THE IMPACT OF THE EGYVIR ON RATS EXPERIMENTAL ANIMALS; A PRECLINICAL STUDY FOR SARS-COV-2 TREATMENT", Journal of Microbiology, Biotechnology and Food Sciences, vol. 13, issue 1, pp. e9658-e9658, 2023. egyvir-jmbfs.pdf
kotb, R. R., A. M. Afif, M. E. EL‑Houseini, M. Ezz‑Elarab, E. B. Basalious, M. M. Omran, and M. S. Abdellateif, " The potential immuno‑stimulating effect of curcumin, piperine, and taurine combination in hepatocellular carcinoma; a pilot study", Discover Oncology, vol. 14, issue 1, pp. 169-183, 2023. cpt_in_hcc_discover_oncology.pdf
Abdelrahman, A. M. N., F. M. Tolba, H. M. Kamal, M. S. Abdellateif, H. A. Ahmed, and N. M. Hassan, "Evaluation of the HOXA9 and MEIS1 genes as a potential biomarker in adult acute myeloid leukemia", Egyptian Journal of Medical Human Genetics, vol. 24, issue 1, pp. 1-11, 2023. hoxa9_meis1_in_aml-ejmhg.pdf
Abdellateif, M. S., and A. - R. N. Zekri, "Stem cell therapy for hepatocellular carcinoma and end-stage liver disease", Journal of the Egyptian National Cancer Institute, vol. 35, 2023. stem_cell_review-jenci.pdf
Abdellateif, M. S., A. K. Bayoumi, and M. A. Mohammed, " c-Kit Receptors as a Therapeutic Target in Cancer: Current Insights", OncoTargets and Therapy , vol. 16, pp. 785–799 , 2023. c-kit_review-oncotargets_and_therapy.pdf
Zekri, A. ‑R. N., A. Bahnassy, M. Mourad, I. Malash, O. Ahmed, and M. S. Abdellateif, "Genetic profling of diferent phenotypic subsets of breast cancer stem cells (BCSCs) in breast cancer patients", Cancer Cell International , vol. 22, pp. 1-15, 2022. bcscs_cancer_cell_international_compressed.pdf
Kandeel, E. Z., L. Refaat, R. Abdel-Fatah, M. Samra, A. Bayoumi, M. S. Abdellateif, H. Abdel-Hady, M. Ali, and medhat khafagy, "Could COVID-19 induce remission of acute leukemia?", Hematology (Amsterdam, Netherlands), vol. 26, issue 1, pp. 870-873, 2021. Abstract

BACKGROUND: COVID-19 viral pandemic caused many mortalities in cancer patients especially those with hematological malignancies. The immunological response to COVID-19 infection is responsible for the outcome of cases whether mild, severe or critical.

CASE PRESENTATION: Two cases presented with moderate COVID-19 viral infection, concomitant with acute myeloid leukemia and T acute lymphoblastic leukemia, respectively. Surprisingly, after the administration of COVID-19 supportive therapy, the cases showed disease remission after a follow-up period of 12 and 5 months, respectively. Additionally, the blast cells dropped to only 3% and 0% in the bone marrow aspirates of those two cases, respectively, after it was 30% in both cases at diagnosis.

CONCLUSION: The immune response that emerged against COVID-19 infection could potentially produce anti-tumor immunity in some patients, or the virus may act as an oncolytic virus. However, further investigations are required to explain this phenomenon, which may help in finding a possible new targeted therapy for these cases.

Bahnassy, A. A., M. S. Abdellateif, and A. - R. N. Zekri, "Cancer in Africa: Is It a Genetic or Environmental Health Problem?", Frontiers in oncology, vol. 10, pp. 604214, 2020. Abstract

Patients of African ancestry have the poorest outcome and the shortest survival rates from cancer globally. This could be attributed to many variables including racial, biological, socioeconomic and sociocultural factors (either single, multiple or combined), which may be responsible for this major health problem. We sought to assess the most common types of cancer that endanger the health of the African people, and tried to investigate the real differences between African and other Non-African patients regarding incidence, prevalence and mortality rates of different cancers. Therefore, identifying the underlying aetiological causes responsible for the increased incidence and mortality rates of African patients will allow for changing the current plans, to make optimized modalities for proper screening, diagnosis and treatment for those African patients, in order to improve their survival and outcomes.

Eissa, M., S. A. B. R. Y. SHAARAWY, and M. S. Abdellateif, "The Role of Different Inflammatory Indices in the Diagnosis of COVID-19.", International journal of general medicine, vol. 14, pp. 7843-7853, 2021. Abstract

AIM: To assess the role of different inflammatory indices in the diagnosis of COVID-19 infection.

METHODS: The neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), platelet-to-lymphocyte ratio (PLR), derived NLR (dNLR), neutrophil to lymphocyte, platelet ratio (NLPR), systemic inflammation index (SII), aggregate index of systemic inflammation (AISI), systemic inflammation response index (SIRI) and C-reactive protein-to-lymphocyte ratio (CRP/L) were assessed in 88 COVID-19 patients compared to 41 healthy control subjects.

RESULTS: The NLR, PLR, NLPR, SIRI, and CRP/L were significantly increased, while LMR was significantly decreased in COVID-19 patients compared to the control group (P = 0.008, 0.011, <0.001, 0.032, 0.002 and P < 0.001; respectively). The AUC for the assessed indices was LMR (0.738, P = 0.008), NLPR (0.721, P < 0.001), CRP/L (0.692, P = 0.002), NLR (0.649, P < 0.001), PLR (0.643, P = 0.011), SIRI (0.623, P = 0.032), dNLR (0.590, P = 0.111), SII (0.571, P = 0.207), and AISI (0.567, P-0.244). Multivariate analysis showed that NLPR >0.011 (OR: 38.751, P = 0.014), and CRP/L >7.6 (OR: 7.604, P = 0.022) are possible independent diagnostic factors for COVID-19 infection.

CONCLUSION: NLPR and CRP/L could be potential independent diagnostic factors for COVID-19 infection.

Bahnassy, A. A., M. M. Saber, M. G. Mahmoud, M. S. Abdellateif, M. Abd El-Mooti Samra, R. A. M. El-Fatah, A. - R. N. Zekri, and S. E. Salem, "The role of circulating tumor cells in metastatic breast cancer: prognostic and predictive value", Molecular biology reports, vol. 45, no. 6: Springer, pp. 2025–2035, 2018. Abstract
n/a